No abstract

Gefitinib (GEF) may increase the risk of corrected QT prolongation (QTc). We aimed to evaluate whether gefitinib increases the risk of corrected QT interval (QTc) prolongation and analyze the associated risk factors.A total of 122 cases of advanced EGFR-mutated non-small cell lung cancer (NSCLC) who received gefitinib therapy from January 2015 to December 2020 were evaluated. The results of at least two resting 12-lead electrocardiogram before and after gefitinib treatment were obtained. The Bazett and Fridericia formulas were used to calculate the QTc interval, and the changes of QTc interval values before and after treatment were evaluated. The correlation between gefitinib and QTc interval prolongation and related risk factors were analyzed.After gefitinib-targeted therapy, 23 patients (18.9%) had a prolonged QTc interval, which increased from a mean of 446 ± 25 ms at baseline to 478 ± 18 ms (P < 0.001). Three of the patients met criteria for Grade 3 QTc prolongation in the common term V5.0 for clinical adverse events. Univariate analysis showed that age (ORR, 1.054; 95% confidence interval [CI], 1.003-1.107; P = 0.038), history of hypertension (ORR, 3.409; 95% CI,; P = 0.01), CCB medication history (ORR, 0.259; 95% CI, 0.094-0.712; P = 0.009), history of lung cancer surgery (ORR, 0.231; 95% CI, 0.064-0.829; P = 0.025), and baseline QT interval (ORR, 0.978; 95% CI, 0.964-0.993; P = 0.004) were important predictors of QTc interval prolongation in patients treated with gefitinib. The results of multivariate analysis showed that the history of lung cancer surgery and the baseline QT interval were important factors affecting QTc interval prolongation in patients treated with gefitinib.Gefitinib increases the risk of QTc prolongation in NSCLC patients, which may be more pronounced in patients with advanced age, hypertension, CCB therapy, lung cancer surgery, and a long QT interval at baseline.

Background: the correlation between BMI and in-hospital mortality of patients with cardiogenic shock is still controversial. We hope to explore whether there is an "obesity paradox" in patients with cardiogenic shock through meta-analysis. Methods PubMed, EMbase and Cochrane databases were searched by computer to include clinical studies related to BMI all-cause mortality of patients with cardiogenic shock. The search time was from the establishment of the database to July 2020. After screening documents, extracting data and evaluating quality according to the inclusion and exclusion criteria, two evaluators used RevMan5.3 statistical software provided by Cochrane Collaboration Network for Meta-analysis. Results There was no significant difference in all-cause mortality (OR=0.86, 95% CI 0.71-1.06, P=0. 16) between the obese and the non-obese patients with cardiogenic shock. In subgroup analysis, in the American population, developed countries and retrospective studies, the all-cause mortality in the obesity group of patients with cardiogenic shock is lower than that of the non-obese group (OR=0.86, 95% CI 0.71-1.06, P=0. 16; OR=0.71,95%CI0.65-0.77, P＜0.00001; OR=0.71，95%CI0.66-0.76, P＜0.00001).Conclusion For patients with cardiogenic shock, there is an "obesity paradox", there is no significant difference in all-cause mortality between obese group and non-obese group. In the subgroup analysis, it was found that the in-hospital all-cause mortality rate of patients with cardiogenic shock in obese group was lower than that in non-obese group according to the country, economic development level and research type. The exact cause of this phenomenon requires more clinical trials and meta-analysis in the future.